AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it will report financial results for the quarter ended March 31, 2016 on Thursday, May 12. AmpliPhi management will host a conference call at 8:30 a.m. Eastern Time on May 13, 2016 to review financial results and provide a corporate update. To access the call, dial 844-745-6357 (US) or 661-378-9813 (outside of the US). The passcode is 10677209. A live webcast will be available in the Events and Presentations section of the Investor Relations page at ampliphibio.com/events-and-presentations. Please log in approximately 10 minutes prior to the scheduled start time. The archived webcast of the call will be available in the Events and Presentations section of the company's website for 30 days. About AmpliPhi Biosciences AmpliPhi Biosciences Corporation (NYSEMKT:APHB) is a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics. AmpliPhi's product development programs target infections that are often resistant to existing antibiotic treatments. AmpliPhi is currently conducting a Phase 1 clinical trial of AB-SA01 for the treatment of Staphylococcus aureus in chronic rhinosinusitis patients and expects to report final data in the second half of 2016. AmpliPhi is also developing bacteriophage therapeutics targeting Pseudomonas aeruginosa and Clostridium difficile in collaboration with a number of leading organizations focused on the advancement of bacteriophage-based therapies.